Dihexa 10mg
Cognitive
$139
Potent HGF/c-Met activator derived from angiotensin IV that promotes synaptogenesis and has demonstrated cognitive enhancement millions of times more potent than BDNF in preclinical models.
Overview
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small peptide derived from angiotensin IV, developed at Washington State University by Joseph Harding. It activates the HGF/c-Met signaling pathway to promote dendritic spine growth and synaptogenesis. In preclinical models it improved cognitive performance in Alzheimer's and scopolamine-impaired animals at doses millions of times lower than BDNF.
Lab Results — 10mg
Every batch is independently tested. Results below are from the Certificate of Analysis for the 10mg batch.
Scientific Details
Molecular Formula
C₂₈H₄₅N₅O₅
Molecular Weight
547.7 g/mol
Form
Lyophilized peptide powder
Solubility
Soluble in DMSO or ethanol; transdermal carrier recommended
Dosage Range
1–3mg daily (research context)
Plasma Half-Life
~3–4 hours
Bioavailability
High transdermal penetration
Resources
Key peer-reviewed studies supporting the efficacy and safety of this compound.
Dihexa: a small peptide with potent pro-cognitive properties
McCoy A.T. et al. — Journal of Pharmacology and Experimental Therapeutics (2013)
Key FindingDihexa reversed scopolamine-induced cognitive deficits and improved Morris water maze performance at nanogram doses, exceeding BDNF potency by seven orders of magnitude.
HGF/c-Met signaling in synaptic plasticity and memory
Akimoto M. et al. — Neuropsychopharmacology (2004)
Key FindingHGF/c-Met pathway activation enhanced dendritic spine density and LTP in hippocampal slices, supporting a role in memory consolidation.
Angiotensin IV and cognitive function
Wright J.W. & Harding J.W. — Brain Research Reviews (2004)
Key FindingAT4 receptor (c-Met) activation by angiotensin IV analogs consistently improved spatial memory and learning across multiple rodent models.